Head-to-head · WeighScore
Eden vs Ro
The verdict
Eden takes it — 90/100 to 78/100.
Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. High-disclosure, high-oversight compounded program with the cleanest verification signals.
Partner links are labeled — we may earn a commission at no cost to you. It never changes the grade.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Eden | Ro |
|---|---|---|
| WeighScore | 90/100 | 78/100 |
| Grade | A− | C+ |
| Scorecard rank | #2 | #24 |
| Semaglutide | $239/mo | Not disclosed |
| Tirzepatide | $349/mo | Not disclosed |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
| Relationship | Partner | Editorial |
Graded #2 · A−
Strengths
- High verification confidence
- Nationwide
- Both molecules
Where it loses points
- Premium pricing
- Compounded only
Graded #24 · C+
Strengths
- Brand-name access + insurance support
- Oral options
- Well-funded platform
Where it loses points
- Does not disclose compounded pricing up front
- Premium positioning
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.